Please login to the form below

Not currently logged in
Email:
Password:

Prexton

This page shows the latest Prexton news and features for those working in and with pharma, biotech and healthcare.

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Lundbeck bolstered its R&D pipeline ahead of the weekend with a 900m ($1.1bn) deal to acquire Prexton Therapeutics and its mid-stage Parkinson’s disease (PD) candidate foliglurax. ... Prexton was set up in 2012 as a spin-out from Merck Serono’s R&D

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics